Figure 1
The effects of intracerebroventricular injection of BM-MSCs on AD model mice. (a) Experimental protocol. At 13 months old, WT and APP/PS1 mice were injected intracerebroventricularly with 1 × 105 BM-MSCs/mouse or vehicle two times at a 2-week interval. (b) The hidden platform test of the MWM test. n = 5–8/group. Values are the means of four trials per day ± SEM. WT + vehicle, F(1.835, 7.341) = 12.10, P = 0.0052; WT + MSC, F(2.099, 10.50) = 7.895, P = 0.0076; APP/PS1 + vehicle, F(2.071, 14.49) = 1.829, P = 0.1951; APP/PS1 + MSC, F(2.834, 19.84) = 4.478, P = 0.0160. One-way ANOVA for repeated measures, by group. **P < 0.01, WT + vehicle vs. APP/PS1 + vehicle; §§P < 0.01, WT + MSC vs. APP/PS1 + vehicle; †P < 0.05, APP/PS1 + vehicle vs. APP/PS1 + MSC. Two-way ANOVA, Tukey post-hoc test, at each day. (c) The probe test of the MWM test. n = 5–8/group. Values are the means ± SEM. **P < 0.01, WT + vehicle vs. APP/PS1 + vehicle; §P < 0.05, WT + MSC vs. APP/PS1 + vehicle; †P < 0.05, APP/PS1 + vehicle vs. APP/PS1 + MSC, two-way ANOVA, Tukey post-hoc test.
